Amiodarone may be more effective than flecainide in patients with atrial fibrillation who are refractory to type IA antiarrhythmic agents. The impact of amiodarone on mortality remains to be determined.
A systematic review 1 including 6 studies of amiodarone with 315 patients and 2 studies of flecainide with 163 patients was abstracted in DARE. After 3 months the proportion of amiodarone-treated patients remaining in sinus rhythm was significantly greater than that expected with the quinidine standard (72.6% compared with 70%, pooled difference 3.5%). After 6 months, the corresponding figure were 71% and 58%, pooled rate difference 13.8%. After 12 months the figures were 60% and 50%, pooled rate difference 10.4%. There was a 29% incidence of adverse effects with amiodarone. For flecainide after 3 months, 48.5% of patients remained in sinus rhythm compared to 70% of the quinidine standard. After 12 months the corresponding figures were 34% and 50%.
Comment: The quality of evidence is downgraded by sparse data and indirectness (there was no direct comparison of amiodarone and flecainide).
1. Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995 Sep 25;155(17):1885-91. [PMID:7677555]
Copyright © 2020 Duodecim Medical Publications Limited.
Amiodarone and flecainide in the treatment of resistant atrial fibrillation
is a sample topic from the Evidence-Based Medicine Guidelines
To view other topics, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.
"Amiodarone and Flecainide in the Treatment of Resistant Atrial Fibrillation." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/452784/all/Amiodarone_and_flecainide_in_the_treatment_of_resistant_atrial_fibrillation.
Amiodarone and flecainide in the treatment of resistant atrial fibrillation. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/452784/all/Amiodarone_and_flecainide_in_the_treatment_of_resistant_atrial_fibrillation. Accessed October 24, 2020.
Amiodarone and flecainide in the treatment of resistant atrial fibrillation. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. Retrieved October 24, 2020, from https://evidence.unboundmedicine.com/evidence/view/EBMG/452784/all/Amiodarone_and_flecainide_in_the_treatment_of_resistant_atrial_fibrillation
Amiodarone and Flecainide in the Treatment of Resistant Atrial Fibrillation [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2020 October 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/452784/all/Amiodarone_and_flecainide_in_the_treatment_of_resistant_atrial_fibrillation.
TY - ELEC
T1 - Amiodarone and flecainide in the treatment of resistant atrial fibrillation
ID - 452784
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452784/all/Amiodarone_and_flecainide_in_the_treatment_of_resistant_atrial_fibrillation
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine